NL-OMON37577已完成3 期
A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, 12-Week Study of Pitavastatin in High-Risk Hyperlipidaemia in Childhood P/266/2011, P267/2011, P268/2011 - PASCAL 401
Kowa Research Europe0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 至 17（—）
入选标准
- •1. Male or female *6 years of age and <17 years of age at randomisation;;2. Have fasting LDL-C levels *160 mg/dL (4.1 mmol/L) or LDL-C *130 mg/dL (3.4 mmol/L) if any of the following additional risk factors are present:;* Male;;* A family history of premature cardiovascular disease defined as a myocardial infarction before age 50 in a second-degree relative or before age 60 in a first-degree relative with at least 1 relative (parent, grandparent, or sibling) affected;;* Presence of low HDL-C (<45 mg/dL) or high TG (>150 mg/dL);;* Presence of high lipoprotein(a) (>75 nmol/L);;09 December 2011 vii12;* Presence of type 2 diabetes mellitus diagnosed by treating physician according to current guidances; or;* Presence of hypertension defined as systolic and diastolic blood pressures above the 95th percentile for age and size;;3. Have not taken any lipid-lowering medications in the 5 weeks prior to screening or in the 4 weeks prior to the lipid qualifying visit at Week -1;;4. Have been adherent to an appropriate diet for at least 8 weeks;;5. Females who are post-menarche must not be pregnant or breast feeding and, if sexually active, must be using a reliable form of contraception; and;6. Written informed consent and assent (if necessary) obtained as required per local regulations.
排除标准
- •1. Unable or unwilling to take study drug;;2. Fasting TG >400 mg/dL (4.5 mmol/L);;3. Homozygous familial hypercholesterolaemia;;4. Other secondary causes of hyperlipidaemia (eg, hypothyroidism, human immunodeficiency virus infection, systemic lupus erythematosus, organ transplantation, previous malignancy, nephrotic syndrome, glycogen storage disease);;5. Previous history of statin intolerance, adverse effects with other statin use, or hypersensitivity to any components of the study drug;;6. Need for non-statin lipid-lowering medications;;7. Apheresis therapy;;8. Use of any concomitant medication which may interfere with the objectives of the study;;9. Type 1 diabetes mellitus;;10. Poorly controlled type 2 diabetes mellitus defined as haemoglobin A1c >9.0% at screening;;11. Severe renal impairment defined as serum creatinine >2.0 mg/dL at screening;;12. Uncontrolled hypertension;;13. Untreated thyroid disease;;14. Severe hepatic impairment, active liver disease, or persistent elevation of alanine transaminase or aspartate transaminase >3 × the upper limit of normal (ULN);;15. Active muscle disease or creatine kinase >3 × ULN (unless explained by exercise);;16. Screening laboratory values within the following age/gender appropriate reference ranges as assessed by the central laboratory:;* Haemoglobin <10 g/dL for males or <9 g/dL for females or;* Alkaline phosphatase >2 × ULN for age;;17. Any other laboratory abnormality that could compromise patient safety because of study participation;;18. Malignancy during the past 5 years;;19. Current smoker or history of drug or alcohol abuse;;20. Hospitalisation for any cause within 30 days prior to the administration of study drug;;21. History of major surgery in the 3 months prior to screening;;22. Any medical condition which, in the judgment of the Investigator, would jeopardize the evaluation of safety and/or constitute a significant safety risk to the patient; or;23. Participation in another clinical study involving an investigational drug during the course of this study or within 30 days prior to signing the informed consent/assent form for this study.
研究者
相似试验
已完成
3 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727/Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapyinherited hyperlipidemia100274241001331710003216familial hypercholesterolemiaNL-OMON39858Sanofi-aventis18
已完成
3 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to evaluate the Efficacy and Safety of SAR236553 (REGN727) in Patients With Heterozygous Familial Hypercholesterolemia and LDL-C higher or equal to 160mg/dL with Their Lipid-Modifying Therapyfamilial hypercholesterolemiainherited hyperlipidemia100274241001331710003216NL-OMON39914Sanofi-aventis11
已完成
3 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients with Heterozygous Familial Hypercholesterolemia Not Adequately Controlled with Their Lipid-Modifying Therapyfamilial hyperchomesterolemiainherited hyperlipidemia100274241001331710003216NL-OMON39622Regeneron Pharmaceuticals, Inc.100
已完成
3 期
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Hypertriglyceridemiahypertriglyceridemia10013317NL-OMON43654IONIS Pharmaceuticals, Inc6
已完成
4 期
A Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Evaluate the Efficacy and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis (EARNEST)inflamatory bowel disease10017969Ulcerative ColitisNL-OMON47815Takeda Development Centre Europe, Ltd10